Member Info for jmfw

Also (don't know if previously connected), Point Biopharma have recently reached an agreement with Bach Sciences. William Bachovchin appears to be who we are working with on AVA6000 at Tufts.

Weathergeek, thanks. Appreciate graphite is THE thing, but royalty payment(s) you suggest a welcome income to cover the burden of management overheads (salaries, admin costs etc).

Any poster have an idea of the value/identity of the add interests (other than Mpokoto). They seem to be gold related. http://armadalecapitalplc.com/gold

Divoc, 815!?

Nelson, you may not be as 'spiked' as you think. My guess is you got accustom shares ,so when they are floated their value can be added to tils sp. 5p, 10p, 50p, £1, who knows, whatever it is, it will sooth the pain & add another dimension to the story.

from rns 21 dec "In addition, the Group has made excellent recent progress with its SARS-CoV-2 lateral flow rapid antigen test programme and we anticipate data from the first clinical trial soon. Our clinical evaluation of the BAMSTM laboratory assay is ongoing at two UK clinical sites that Avacta has established and we have made significant commercial progress for all of our coronavirus testing solutions, establishing scalable routes to market for these products to meet the anticipated very high demand. I look forward to reporting on progress on all these fronts in the New Year and to a very exciting 2021 for the Group."
from rns 23 nov "In preparation for clinical validation of the lateral flow test Avacta is working on both saliva and anterior nasal swab samples. Anterior nasal swabs sample the easily accessible parts of the nose and are therefore painless and straightforward to administer, unlike nasopharyngeal swabs which are generally regarded as painful and unpleasant. Avacta and its partners will continue to develop both sampling methods in parallel in order to bring high performance COVID-19 tests to market quickly to suit a range of use cases. "

MB, why do you care what happens to avacta? You're not invested, so is it that you feel others are ignorant to the (potential) pitfalls? Pretty condescending if so.

Old news isn't it? Article dated 25 October.

Tayboy https://www.fortressdiagnostics.com/

From rns 23 nov "In preparation for clinical validation of the lateral flow test Avacta is working on both saliva and anterior nasal swab samples. Anterior nasal swabs sample the easily accessible parts of the nose and are therefore painless and straightforward to administer, unlike nasopharyngeal swabs which are generally regarded as painful and unpleasant. Avacta and its partners will continue to develop both sampling methods in parallel in order to bring high performance COVID-19 tests to market quickly to suit a range of use cases."
rns 21 dec "In addition, the Group has made excellent recent progress with its SARS-CoV-2 lateral flow rapid antigen test programme". Note it doesn't say 'excellent recent progress with the anterior nasel swab'.
We have 2 tests.

observations re Nasdaq

short volume some 40% yesterday!?
'bot' still active
well above average trading volume again today
looking forward to the (imminent?) (hopefully positive) news & it's effect on the sp

make a vaccine???

As you must realise, there are numerous 'big claims' on these types of boards. Some genuine, but many mischevious. Time is the reckoner.

Short vol yesterday was nearly 32%,previous day 21%. We peaked at around $2.58, but finished at $2.13. The 'bot' is still operational. We now have some clarity re: main market listing, but think something positive on Foralumab will be the driver & reinforce/change sentiment.

Will be pleased to receive clarity on Accustem as think this will also have positive impact on the tils sp.

Profcheese has alluded to these. There is an oft expressed allusion that avct has provided timelines, so, to satisfy my curiousity, can anyone provide details of what they were, when they were advised & by what method (rns, video chat, etc) they were relayed to the shareholders. Thanks

Hants...definitely MY last post. Why indulge in pure speculation? It seems highly likely that over the 2-3 weeks all will be revealed. Either AVCT will have a test, or they won't. Whatever the outcome there will be jeering from either side of 'coin'.

ODX's board, or AVCT's board will be full of bloated &/or deflated egos. Personally, I don't care what ODX achieve, my interest is in Avacta, so am content to live or die with that, but I do find it odd that so many who clearly have no belief, or, probably, no investment, keep posting negative speculation, or just plain rubbish.
Anyway, as with MB, rip.

MB...affimers no good? Think quite a lot of research out there that proves they work. You obviously follow Avacta so will have read the quite recent links to both Bruker & Astra Zeneca re BAMS. On top of which both Moderna & LG Chem have extended collaborations with avct. I'm sure they wouldn't have done so had they not proved to be, at least, satisfactory.

Anyway, enough banter. RIP.

Your chairman was also delighted.. "I am delighted that we have received approval to sell the Mologic ELISA antibody test in India as this is a key target market. We have an established direct sales team and we believe a reliable and high-performance antibody test will be very attractive to our laboratory customers. India is one of the fastest growing economies in the world and has a population of over 1.3 billion people. Clearly this is an important market for us to target and I look forward to updating shareholders on our commercial traction."
Presumeably won't end well.

hants/mb....."I am delighted with the excellent progress that has been made with BBI Solutions in developing a scalable version of a lateral flow rapid SARS-CoV-2 antigen test with sensitivity in the expected clinical range for spike protein. BBI Solutions is an excellent development partner and I am particularly pleased at how well the teams are working together to shorten the timeline as much as possible without compromising quality. "

That statement from AS in the last rns seems pretty clear to me. Why do you think it's not true?